Modality
mAb
MOA
GLP-1ag
Target
PCSK9
Pathway
Cell Cycle
MGBreast CaRB
Development Pipeline
Preclinical
~Dec 2015
→ ~Mar 2017
Phase 1
~Jun 2017
→ ~Sep 2018
Phase 2
Dec 2018
→ Feb 2025
Phase 2Current
NCT07724786
1,343 pts·RB
2019-03→2025-02·Recruiting
NCT04798432
2,409 pts·RB
2018-12→TBD·Recruiting
3,752 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-071.1y agoPh2 Data· RB
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
P2
Recruit…
P2
Recruit…
Catalysts
Ph2 Data
2025-02-07 · 1.1y ago
RB
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07724786 | Phase 2 | RB | Recruiting | 1343 | HAM-D |
| NCT04798432 | Phase 2 | RB | Recruiting | 2409 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |